ILYX-002: Dry Eye Disease Phase 2 Trial Results
- ILYX-002,a topical immunomodulator,has demonstrated positive Phase 2 results in treating moderate to severe dry eye disease associated with systemic autoimmune or inflammatory conditions.
- Houman Hemmati, head of medical at Iolyx, told Healio that ILYX-002 is a potent, broad-spectrum anti-inflammatory agent.
- ILYX-002 is the first drug Iolyx has advanced to Phase 2, reflecting the company's focus on the intersection of immunology and ophthalmology.
ILYX-002, a topical immunomodulator, shows promise in treating dry eye disease linked to systemic autoimmune or inflammatory conditions. Phase 2 trial results reveal significant improvements within 15 days, targeting multiple pathways involved in dry eye. Patients experienced marked relief, with durable responses and minimal side effects. this marks a turning point in the treatment of immune-mediated dry eye, offering steroid-like benefits without the adverse effects. The drug demonstrated a –1.41-point advantage in corneal staining after 15 days, with lasting effects. Iolyx Therapeutics is now preparing for phase 3 trials, aiming for commercialization. Stay informed on potential breakthroughs. For breaking news, go to News Directory 3. Discover what’s next in dry eye treatment.
New Immunomodulator Shows promise for Systemic Dry Eye Relief
ILYX-002,a topical immunomodulator,has demonstrated positive Phase 2 results in treating moderate to severe dry eye disease associated with systemic autoimmune or inflammatory conditions. Iolyx Therapeutics announced the findings, highlighting the drug’s potential to address multiple pathways involved in dry eye.
key Takeaways:
- Dry eye disease linked to systemic autoimmune or inflammatory conditions saw meaningful improvement with ILYX-002 after 15 days.
- ILYX-002 targets multiple pathways, including Th17/Th1, implicated in dry eye.
Dr. Houman Hemmati, head of medical at Iolyx, told Healio that ILYX-002 is a potent, broad-spectrum anti-inflammatory agent. It hones in on specific pathways involved in dry eye, making it an ideal treatment for patients with immune-mediated dry eye disease, Hemmati said.
ILYX-002 is the first drug Iolyx has advanced to Phase 2, reflecting the company’s focus on the intersection of immunology and ophthalmology. The goal is to create drugs that offer the benefits of steroids without the immunosuppressive effects and side effects, Hemmati noted.
patients treated twice daily with ILYX-002 showed a –1.41-point least squares mean advantage in total corneal fluorescein staining after 15 days, increasing to –1.78 points at day 57 (P = .0021), compared to the control group. The drug also resulted in a –1.1-point least squares mean difference in lissamine green conjunctival staining at day 15 (P = .0425), which remained at –0.97 points at day 57.
Mark Hinds, principal investigator of the ILYX-002-201 trial, said the rapid effect is remarkable, typically seen only with topical steroids. There were no discontinuations due to tolerability or IOP concerns, and the benefit lasted through week 8, confirming a durable response.
The release also noted “meaningful 10- to 20-point improvements” across various symptom and quality-of-life scores in patients treated with ILYX-002. Most adverse events were mild to moderate.
Hemmati believes ILYX-002 coudl be effective for dry eye disease in general, irrespective of autoimmunity. he noted that the general dry eye population tends to respond well to topical anti-inflammatories.
Iolyx plans to start it’s Phase 3 program later this year, aiming for completion in 2028. The program will include two registration studies with about 300 patients each, and a 12-month safety extension trial involving around 150 patients. The Phase 3 trials will use the commercial unit dose product, which is preservative-free, to prepare for immediate commercialization upon approval, he said.
For more information:
Houman Hemmati,MD,PHD, can be reached at hhemmati@iolyx.com or X @houmanhemmati.